belimumab + dexamethasone + etoposide + hydroxychloroquine

This is a combination therapy consisting of four active pharmaceutical ingredients:

• Belimumab is a recombinant human monoclonal antibody that binds to and inhibits B lymphocyte stimulator (BLyS), reducing the survival of B cells, which are implicated in autoimmune diseases such as systemic lupus erythematosus (SLE).
• Dexamethasone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressant properties.
• Etoposide is a topoisomerase II inhibitor used primarily as an antineoplastic agent in various cancers.
• Hydroxychloroquine is an antimalarial and disease-modifying anti-rheumatic drug (DMARD) that modulates immune system activity, commonly used for SLE and rheumatoid arthritis.

This specific four-drug combination does not have an established brand or code name, nor does it represent a standard fixed-dose product. Each component has distinct mechanisms of action targeting different aspects of immune modulation or cytotoxicity. Such combinations may be considered in complex autoimmune or oncologic settings but are not standard therapy.